Frederick G. Wasserman - 08 Jun 2021 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Reporting relationship: Director
Issuer ticker: MRKR
Reported as of: 08 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2021, 18:57:40 UTC
Prior SEC filing: 20 May 2021
Next SEC filing: 05 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Michael Loiacono, Attorney-in-Fact

Key filing fact

Frederick G. Wasserman filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 10 Jun 2021.

Key facts

This page summarizes Frederick G. Wasserman's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jun 2021, 18:57.

Change

Previous filing in this sequence was filed on 20 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRKR transaction

Common Stock

Award

Transaction value: $0
Shares: +12,658
Change %: +24%
Price: $0.000000
Shares after: 65,223
Date: 08 Jun 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting.